
A new £20m high-security laboratory using robotics, artificial intelligence (AI) and human organoids to accelerate drug and vaccine development for …

A pilot study conducted by the University of Liverpool has found that mass rapid testing reduced COVID-19 cases in Liverpool …

The Liverpool-based vaccine-maker Sequiris is investing £40 million into the expansion of its operations in the Speke area of Liverpool. …
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns

